Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 16;373(3):290-1.
doi: 10.1056/NEJMc1500286.

Linezolid for XDR-TB--Final Study Outcomes

Myungsun Lee  1 , Sang Nae Cho, Clifton E Barry 3rd, Taeksun Song, Youngran Kim, Ina Jeong
Affiliations

Linezolid for XDR-TB--Final Study Outcomes

Myungsun Lee et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

References

    1. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. The New England journal of medicine 2012;367:1508–18. - PMC - PubMed
    1. Hillemann D, Rusch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrobial agents and chemotherapy 2008;52:800–1. - PMC - PubMed
    1. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. The European respiratory journal 2015;45:161–70. - PubMed
    1. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010;14:241–2. - PubMed
    1. Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. The European respiratory journal 2012;40:1430–42. - PubMed

MeSH terms